Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
Clinical-stage biopharmaceutical company, oral small molecule therapies for metabolic & immune diseases, including GLP-1 receptor agonists.
Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapies for metabolic and immune-related diseases, based in Shanghai, China, with an additional office in Cambridge, Massachusetts. The enterprise currently operates with a workforce of 21 to 50 employees and has secured $39.83 million in total venture funding to advance its clinical pipeline. The firm licenses its therapeutic assets to major pharmaceutical corporations, highlighted by a 2023 agreement granting AstraZeneca international rights to its obesity drug candidate ECC5004 for $185 million upfront and up to $1.83 billion in milestone payments. This strategic partnership and subsequent investment increased the corporate valuation to $498 million, prompting plans for a Hong Kong initial public offering sponsored by Jefferies and BofA Securities. Eccogene was officially founded in 2018 by former Eli Lilly scientists Jingye Zhou and Jianfeng Xu.
Eccogene has raised $25.2M across 1 funding round.
Eccogene has raised $25.2M in total across 1 funding round.
Eccogene has raised $25.2M in total across 1 funding round.
Eccogene's investors include New Alliance Capital, Zhangjiang Healthcare Venture Capital, Delos Capital, Rockbleu Capital, YuFu Investment.
Eccogene has raised $25.2M across 1 funding round. Most recently, it raised $25.2M Series B in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 12, 2023 | $25.2M Series B | NEW Alliance Capital, Zhangjiang Healthcare Venture Capital | Delos Capital, Rockbleu Capital, Yufu Investment | Announced |